We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+22.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$386M
AUM Growth
+$36.6M
Cap. Flow
-$1.12M
Cap. Flow %
-0.29%
Top 10 Hldgs %
62.47%
Holding
49
New
11
Increased
11
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
PTE
PolarityTE, Inc. Common Stock
PTE
+$19M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$9.29M
3
VRDN icon
Viridian Therapeutics
VRDN
+$8.46M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$7.76M
5
XNCR icon
Xencor
XNCR
+$6.2M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$19.9M
2
AXGN icon
Axogen
AXGN
+$12.1M
3
ARDX icon
Ardelyx
ARDX
+$5.73M
4
ABLX
Ablynx NV
ABLX
+$4.91M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.06M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
$5.83M 1.51%
+265,000
New +$6.09M
CMRX
27
DELISTED
Chimerix, Inc.
CMRX
$5.47M 1.42%
1,150,000
+550,000
+92% +$2.63M
AMRN
28
Amarin Corp
AMRN
$297M
$5.41M 1.4%
87,500
+250
+0.3% +$15.5K
BFRA
29
DELISTED
Biofrontera AG American Depositary Shares
BFRA
$4.75M 1.23%
+391,400
New +$5.3M
FOMX
30
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.83M 0.99%
250,000
-700,000
-74% -$3.6M
EPZM
31
DELISTED
Epizyme, Inc
EPZM
$3.73M 0.96%
275,000
+205,000
+293% +$3.19M
ARQL
32
DELISTED
Arqule Inc
ARQL
$2.32M 0.6%
+420,000
New +$1.6M
PLX icon
33
Protalix BioTherapeutics
PLX
$210M
$1.33M 0.35%
310,000
-16,000
-5% -$71.1K
CTIC
34
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$803K 0.21%
+161,400
New +$706K
GRDX
35
GridAI Technologies Corp
GRDX
$28.6M
$417K 0.11%
+1
New +$369K
BLRX
36
BioLineRX
BLRX
$12.1M
$222K 0.06%
417
– –
ARDX icon
37
Ardelyx
ARDX
$986M
– –
-1,135,600
Closed -$5.73M
ASRT
38
DELISTED
Assertio
ASRT
– –
-10,000
Closed -$3.95M
FBIO icon
39
Fortress Biotech
FBIO
$93.4M
– –
-21,000
Closed -$1.43M
QTRX icon
40
Quanterix
QTRX
$125M
– –
-150,000
Closed -$2.56M
SNDX icon
41
Syndax Pharmaceuticals
SNDX
$1.8B
– –
-222,500
Closed -$3.17M
SYRS
42
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-7,407
Closed -$961K
QTNT
43
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-1,500
Closed -$282K
ZSAN
44
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-2,857
Closed -$504K
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,095,100
Closed -$4.06M
ABLX
46
DELISTED
Ablynx NV
ABLX
– –
-90,000
Closed -$4.91M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2018 Portfolio in Review

As of Q2 2018, Opaleye Management held 49 positions worth $386M, up 10% from $350M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management's Q2 2018 filing shows 11 new, 11 increased, 7 reduced and 13 closed positions. Its largest new stake was PolarityTE, Inc. Common Stock: 32,000 shares worth $18.8M. The largest sale was Blueprint Medicines, an estimated $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

  • Opaleye Management's largest Q2 2018 buy was PolarityTE, Inc. Common Stock: 32,000 shares worth $18.8M.
  • Opaleye Management added most to TG Therapeutics in Q2 2018, an estimated $4.82M increase.
  • Opaleye Management's biggest Q2 2018 reduction was Blueprint Medicines, cutting an estimated $19.9M.
  • Opaleye Management fully exited Ardelyx in Q2 2018, selling an estimated $5.73M.
  • Opaleye Management's ten largest holdings make up 62% of its $386M portfolio in Q2 2018.
  • Opaleye Management opened 11 new positions and closed 13 in Q2 2018.
  • Opaleye Management's portfolio value rose 10% quarter-over-quarter to $386M.

Based on Opaleye Management's 13F filing for Q2 2018, filed 14 Aug 2018.